<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72002">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656642</url>
  </required_header>
  <id_info>
    <org_study_id>GP28384</org_study_id>
    <nct_id>NCT01656642</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma</brief_title>
  <official_title>A Phase Ib, Open-Label Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansi on study of
      MPDL3280A in combination with Vemurafenib (Zelboraf®) in previously untreated patients with
      BRAFV600-mutation positive metastatic melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>21 days following the first administration of MPDL3280A</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of dose-limiting toxicities (DLTs)</measure>
    <time_frame>21 days following the first administration of MPDL3280A</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0</measure>
    <time_frame>approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of adverse events and laboratory abnormalities graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0</measure>
    <time_frame>approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events and laboratory abnormalities graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0</measure>
    <time_frame>approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-MPDL3280A antibodies</measure>
    <time_frame>approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs, including electrocardiograms (ECGs)</measure>
    <time_frame>approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory results</measure>
    <time_frame>approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cycles and dose intensity of each component of the treatment regimen</measure>
    <time_frame>approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPDL3280A + Zelboraf (vemurafenib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPDL3280A + Zelboraf (vemurafenib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPDL3280A + Zelboraf (vemurafenib)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPDL3280A</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib (Zelboraf®)</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic documentation of metastatic melanoma, with BRAFV600 mutation
             as assessed by cobas® 4800 BRAF V600 Mutation Test. Origin of the primary tumor must
             be known and may be of skin, mucosal, or acral locations but not of ocular origin.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic and end organ function

          -  Measurable disease per RECIST v1.1

          -  For female patients of childbearing potential and male patients with partners of
             childbearing potential, agreement to use an effective form of contraception  and to
             continue its use for 6 months after discontinuation from the study

        Exclusion Criteria:

          -  Receipt of prior systemic anti-cancer therapy for unresectable, locally advanced or
             metastatic melanoma

          -  Receipt of prior MAPK inhibitor pathway agents, including MEK kinase inhibitor and
             BRAF kinase inhibitor

          -  Major surgical procedure within 28 days prior to Day 1 or anticipation of need for a
             major surgical procedure during the course of the study

          -  Radiotherapy &lt;/= 14 days prior to Day 1

          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade &lt;= 1
             except for alopecia

          -  Current severe, uncontrolled systemic disease excluding cancer

          -  Known clinically significant liver disease

          -  Known primary central nervous system (CNS) malignancy or untreated or active CNS
             metastases

          -  Any ongoing malignancy other than melanoma

          -  History or risk of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, risk of pulmonary toxicity, or evidence of
             active pneumonitis on screening chest CT scan

          -  History of HIV or hepatitis C infection

          -  Active tuberculosis

          -  Severe infections within 4 weeks prior to Cycle 1 Day 1 or Signs or symptoms of
             infection within 2 weeks prior to Cycle 1 Day 1

          -  Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1

          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study

          -  History of clinically significant cardiac or pulmonary dysfunction

          -  Treatment with systemic immunosuppressive medications within 4 weeks prior to Cycle 1
             Day 1

          -  Bisphosphonate therapy for symptomatic hypercalcemia

          -  Pregnant or lactating women

          -  Any vemurafenib-specific exclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GP28384 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>August 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-L1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>antiPD-L1</keyword>
  <keyword>MPDL3280A</keyword>
  <keyword>Melanoma</keyword>
  <keyword>BRAF</keyword>
  <keyword>MPDL320A</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
